European Biotech Acquisition Stock Z Score

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

According to the company's disclosures, European Biotech Acquisition has a Z Score of 0.0. This is 100.0% lower than that of the Financial Services sector and about the same as Shell Companies (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze European Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of European Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of European Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the European Biotech Acq information on this page should be used as a complementary analysis to other European Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.